

Advent Pharma Limited

Head office: Rupayan Karim Tower,
 Level # 10, 80 Kakrail, Ramna, Dhaka-1000, Bangladesh

PRICE SENSITIVE INFORMATION


This is for kind information of all concerned the Board of Directors of Advent Pharma Limited in its Board Meeting held on 30th day of January 2020 at 03.30 pm considered and approved of the un-audited Quarterly Financial Statements of the Company for the 2nd Quarter (Q2) period from July to December 2019 (Half yearly) and took the following price sensitive decisions.

Particulars	October to December, 2019	October to December, 2018	July to December, 2019	July to December, 2018
Earnings Per Share (EPS)	0.52	0.57	1.15	1.07
Net Operating Cash Flow (NOCF) per share			1.35	1.49
	As at 31 December 2019		As at 30 June 2019	
Net Asset Value (NAV) per share	13.24		13.50	

The detail of the Un-audited Quarterly Financial Statements of the Company for the 2nd Quarter (Q2) period from July to December 2019 (Half yearly) are also available the web site of the company at www.adventpharmabd.com

By order of the Board

Dated: Dhaka
 30 January 2020



Md. Ikramul Islam
 Company Secretary